A multi-centre, randomised, double blind, placebo controlled trial to investigate the effect of bicalutamide (Casodex) 150mg on the pharmacokinetics of midazolam in prostate cancer patients
Latest Information Update: 06 Feb 2010
At a glance
- Drugs Bicalutamide (Primary) ; Midazolam
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 13 Dec 2005 New trial record.